WO2007080919A1 - 動物細胞を無血清培養するための培地用添加剤、キット及びこれらの利用 - Google Patents
動物細胞を無血清培養するための培地用添加剤、キット及びこれらの利用 Download PDFInfo
- Publication number
- WO2007080919A1 WO2007080919A1 PCT/JP2007/050232 JP2007050232W WO2007080919A1 WO 2007080919 A1 WO2007080919 A1 WO 2007080919A1 JP 2007050232 W JP2007050232 W JP 2007050232W WO 2007080919 A1 WO2007080919 A1 WO 2007080919A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- culture medium
- medium
- culture
- medium additive
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0031—Serum-free culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/16—Magnesium; Mg chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/12—Hepatocyte growth factor [HGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
Definitions
- the present invention relates to a composition, kit, and use thereof that are added to a culture medium for animal cells, and more specifically, for culturing animal cells under serum-free or low-serum conditions.
- the present invention relates to yarns and products, kits and their use.
- a mesenchymal stem cell is one of somatic stem cells present in tissues such as bone marrow, and is a stem cell having multipotency to differentiate into fat cells, bone cells, chondrocytes, etc., and self-proliferating ability.
- mesenchymal stem cells are used as transplantation cells in the field of regenerative medicine, and the diseases to which mesenchymal stem cells are applied are bone defects, cartilage defects, periodontal diseases, myocardial infarction, refractory skin diseases , Osteoporosis, osteoarthritis, spinal cord injury, hematopoietic support, suppression of rejection in organ transplantation, etc.
- the number of diseases to which mesenchymal stem cells are applied is expected to increase further (for example, cerebral infarction, obstructive arteriosclerosis, kidney disease, etc.).
- mesenchymal stem cells exist in tissues such as bone marrow and periosteum.
- the mesenchymal stem cells from which these biological tissue forces are also collected are proliferated and further differentiated into desired cells to prepare tissues that can be used in tissue regeneration medicine.
- the cells from which tissue force has been collected are sufficiently proliferated. It is necessary to let
- animal cells are cultured using a medium supplemented with 5 to 20% serum derived from a non-human animal such as urchin fetal serum.
- serum is used as a nutrient source for promoting cell growth and Z or proliferation in vitro, or as a source of physiologically active substances such as hormones.
- serum is very expensive, and because it is a natural product, there is a difference in ingredients from mouth to mouth.
- cell strength after culturing needs to be purified in order to remove serum-derived proteins and the like, and the work becomes complicated. Furthermore, it is mixed in serum There is a risk of contamination of cultured cells by unknown pathogens (viruses, pathogenic prions, etc.).
- Patent Documents 3 and 4 A method of culturing chondrocytes for therapeutic application by incorporating a fatty acid in addition to a growth factor in a serum-free medium is also known (see, for example, Patent Documents 3 and 4). Furthermore, Patent Document 5 describes a method and a composition for culturing neural stem cells for a long period of time.
- Patent Document 2 Japanese Patent Publication “JP-A-8-308561 (Publication date: November 26, 1996)”
- Patent Document 3 Japanese Patent Publication “JP-A-9-191874 (Publication Date: July 29, 1997)”
- Patent Document 4 Japanese Patent Publication “Special Table 2005-515777 Publication (published June 2, 2005)” [Patent Document 4]
- Patent Document 5 Japanese Patent Publication “Special Table 2002-529071 Publication (published on September 10, 2002)” [Patent Document 5]
- the present invention has been made in view of the above problems, and an object of the present invention is to provide a technique having an effect of promoting the growth of animal cells comparable to a 10% serum-containing medium while being a serum-free medium. It is in.
- the culture medium additive according to the present invention comprises at least three growth factors selected from the group consisting of FGF, PDGF, TGF—8 and HGF, and at least 1 for culturing animal cells without serum. It contains two phospholipids.
- the phospholipid includes phosphatidic acid, lysophosphatidic acid, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine, and Phosphatidylglycerol is also preferably selected from the group consisting of:
- the culture medium additive according to the present invention preferably further contains at least one fatty acid.
- the fatty acid is selected from the group consisting of linoleic acid, oleic acid, linolenic acid, arachidonic acid, myristic acid, palmitoyl acid, normitic acid, and stearic acid power. Particularly preferred are the essential nutritional fatty acids linoleic acid, linolenic acid and arachidonic acid.
- the culture medium additive of the present invention may further contain cholesterol.
- the culture medium additive according to the present invention may further contain at least two factors selected from the group consisting of EGF, CTGF, VEGF and ascorbic acid compound strength.
- the culture medium additive of the present invention may further contain a lipid antioxidant.
- the lipid antioxidant is DL-a-tocopherol acetate (vitamin E), L-glutathione (L-glutthione) or 2-mercap.
- Toethanol (2-mercaptoethanol) is preferred, but other reducing agents.
- the culture medium additive of the present invention may further contain lithium chloride.
- the culture medium additive of the present invention may further contain a surfactant.
- the surfactant is Pluronic F-68 or
- Tween 80 is preferred, but other surfactants may be used.
- the culture medium additive of the present invention may further contain insulin, transferrin, and selenate.
- the culture medium additive of the present invention may further contain dexamethasone or another glucocorticoid.
- the animal cell is preferably an unbroken cell.
- the animal cell is preferably a mesenchymal stem cell.
- the animal cell is preferably a cell (for example, a monkey kidney-derived cos cell) that has lost a special differentiation ability and is close to an undifferentiated state. .
- the culture medium according to the present invention is characterized in that it contains a component constituting the above-mentioned supplementary supplement for medium for serum-free culture of animal cells.
- the culture method according to the present invention is characterized by including a step of culturing animal cells in the above culture medium for serum-free culture of the animal cells.
- the culture medium additive kit according to the present invention comprises the above culture medium additive for serum-free culturing of animal cells.
- the culture medium additive kit according to the present invention provides FGF, P for culturing animal cells in serum-free culture.
- It is characterized by having at least three growth factors selected from the group consisting of DGF, TGF—8 and HGF, and at least one phospholipid separately.
- the culture medium additive kit according to the present invention preferably further comprises at least one fatty acid.
- the phospholipid includes phosphatidic acid, Preferably, lysophosphatidic acid, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine, and phosphatidylglycerol are also selected.
- the fatty acid is preferably selected from the group consisting of linoleic acid, oleic acid, linolenic acid, arachidonic acid, myristic acid, palmitoyl acid, palmitic acid, and stearic acid. Better ,.
- the culture medium additive kit of the present invention may further comprise cholesterol.
- the culture medium additive kit of the present invention may further comprise at least two factors selected from the group consisting of EGF, CTGF, VEGF, and ascorbine oxide.
- the culture medium additive kit according to the present invention may further include a lipid acidification inhibitor.
- the lipid antioxidant is DL-a tocopherol acetate (vitamin E), L-glutathione (L-glutthione) or 2-mercaptoethanol (2-mercaptoethanol). Although it is preferred, it may be another reducing agent.
- the culture medium additive kit of the present invention may further comprise lithium chloride.
- the culture medium additive kit of the present invention may further include a surfactant.
- the surfactant is Pluronic F-68 or
- Tween 80 is preferred, but other surfactants may be used.
- the culture medium additive kit of the present invention may further include insulin, transferrin, and selenate.
- the culture medium additive kit according to the present invention may further include dexamethasone or other darcocorticoid.
- the animal cell is an unbroken cell.
- the animal cell is preferably a mesenchymal stem cell.
- the animal cell may be a cell that has lost a special separation ability and is close to an undivided state (for example, a monkey kidney-derived COS cell). Like Yes.
- the culture medium according to the present invention is characterized by containing the components provided in the above-mentioned additive kit for medium for serum-free culture of animal cells.
- the culture method according to the present invention is characterized by including a step of culturing animal cells in the above-mentioned culture medium in order to culture the animal cells without serum.
- the culture method according to the present invention comprises at least three growth factors selected from the group consisting of FGF, PDGF, TGF—8 and HGF, and at least one for culturing animal cells in serum-free culture. It includes the step of simultaneously adding phospholipids to the basal medium.
- the culture method according to the present invention preferably includes a step of further adding at least one fatty acid to the basal medium!
- the culture medium additive according to the present invention comprises at least three proliferations selected from the group consisting of FGF, PDGF, TGF-j8, and HGF in order to continuously subculture stem cells while maintaining differentiation potential. It is characterized by containing a factor as well as at least one phospholipid.
- the culture medium additive according to the present invention preferably further contains at least one fatty acid.
- the culture medium additive kit according to the present invention is at least selected from the group consisting of FGF, PDGF, TGF—8 and HGF in order to continuously culture stem cells while maintaining differentiation potential. Featuring three growth factors and at least one phospholipid
- the culture medium additive kit according to the present invention preferably further comprises at least one fatty acid.
- the culture medium according to the present invention is characterized by containing at least three growth factors selected from the group consisting of FGF, PDGF, TGF- ⁇ and HGF, and at least one phospholipid.
- the culture medium according to the present invention preferably further contains at least one fatty acid.
- the culture method according to the present invention is for continuously subculturing stem cells while maintaining differentiation ability. And a step of simultaneously adding at least three growth factors selected from the group consisting of FGF, PDGF, TGF-j8 and HGF and at least one phospholipid to the basal medium.
- the culture method according to the present invention preferably includes a step of further adding at least one fatty acid to the basal medium!
- the culture medium additive according to the present invention is a combination of PDGF, at least one phospholipid, at least one fatty acid, and EGF, CTGF, VEGF, and ascorbic acid for culturing primary cultured stem cells. It is characterized by containing at least two factors selected from the group of physical strength.
- the culture medium additive of the present invention may further contain at least one factor selected from the group consisting of FGF, TGF- ⁇ , and HGF force.
- the phospholipid is phosphatidic acid, lysophosphatidic acid, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, phosphatidyl.
- Choline, and phosphatidylglycerol are also preferably selected from the group consisting of:
- the fatty acid is selected from the group consisting of linoleic acid, oleic acid, linolenic acid, arachidonic acid, myristic acid, palmitoyl acid, normitic acid, and stearic acid power. Particularly preferred are the essential nutritional fatty acids linoleic acid, linolenic acid and arachidonic acid.
- the culture medium additive of the present invention may further contain cholesterol.
- the culture medium additive of the present invention may further contain a lipid antioxidant.
- the lipid antioxidant is preferably DL-a-tocopherol acetate (vitamin E).
- the culture medium additive of the present invention may further contain a surfactant.
- the surfactant is Pluronic F-68 or
- Tween 80 is preferred, but other surfactants may be used.
- the culture medium additive of the present invention may further contain insulin, transferrin, and selenate. [0067] The culture medium additive of the present invention may further contain dexamethasone or another glucocorticoid.
- the culture medium additive kit according to the present invention comprises PDGF, at least one phospholipid, at least one fatty acid, and EGF, CTGF, VEGF and ascorbic acid compound for culturing primary cultured stem cells. It is characterized by having at least two factors selected from the group.
- the culture medium additive kit according to the present invention may further include at least one factor selected from the group consisting of FGF, TGF- ⁇ , and HGF power.
- the phospholipid contains phosphatidic acid, lysophosphatidic acid, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, phosphatidyl.
- choline and phosphatidyl glycerol are also selected from the group.
- the fatty acid is selected from the group consisting of linoleic acid, oleic acid, linolenic acid, arachidonic acid, myristic acid, noremitoylic acid, palmitic acid, and stearic acid. Linoleic acid, linolenic acid and arachidonic acid, which are essential nutritional fatty acids, are particularly preferred.
- the culture medium additive kit of the present invention may further comprise cholesterol.
- the culture medium additive kit according to the present invention may further include a lipid acidification inhibitor.
- the lipid antioxidant is preferably DL-hytocopherol acetate (vitamin E)! /.
- the culture medium additive kit of the present invention may further include a surfactant.
- the surfactant is preferably Pluronic F-68 or Tween 80, but may be other surfactants.
- the culture medium additive kit of the present invention may further comprise insulin, transferrin, and selenate.
- the culture medium additive kit according to the present invention may further include dexamethasone or other darcocorticoid.
- the culture method according to the present invention includes PDGF, at least a method for culturing primary cultured stem cells. Characterized in that it comprises the step of simultaneously adding one phospholipid, at least one fatty acid, and at least two factors selected from the group consisting of EGF, CTGF, VEGF and ascorbic acid to the basal medium. RU
- the culture method according to the present invention may further include a step of adding at least one factor selected from the group consisting of FGF, TGF- ⁇ , and HGF to the basal medium.
- the medium additive according to the present invention comprises TGF- ⁇ , PDGF, at least one phospholipid, at least one fatty acid, as well as EGF, CTGF, VEGF in order to continuously subculture mouse fibroblasts. And at least two factors selected from the group consisting of ascorbic acid compounds.
- the culture medium additive of the present invention may further contain FGF and / or HGF.
- the phospholipid is phosphatidic acid, lysophosphatidic acid, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, phosphatidyl.
- Choline, and phosphatidylglycerol are also preferably selected from the group consisting of:
- the fatty acid is selected from the group consisting of linoleic acid, oleic acid, linolenic acid, arachidonic acid, myristic acid, palmitoyl acid, normitic acid, and stearic acid power. Particularly preferred are the essential nutritional fatty acids linoleic acid, linolenic acid and arachidonic acid.
- the culture medium additive of the present invention may further contain cholesterol.
- the culture medium additive of the present invention may further contain a lipid antioxidant.
- the lipid antioxidant is preferably DL-a-tocopherol acetate (vitamin E).
- the culture medium additive of the present invention may further contain a surfactant.
- the surfactant is Pluronic F-68 or
- Tween 80 is preferred, but other surfactants may be used.
- the culture medium additive of the present invention may further contain insulin, transferrin, and selenate.
- the culture medium additive according to the present invention includes dexamethasone or other group.
- a lucocorticoid may further be contained.
- the culture medium additive kit according to the present invention comprises TGF- ⁇ , PDGF, at least one phospholipid, at least one fatty acid, and EGF, CTGF, in order to continuously subculture mouse fibroblasts. It comprises at least two factors selected from the group consisting of VEGF and ascorbic acid compounds.
- the culture medium additive kit of the present invention may further comprise FGF and Z or HGF.
- the phospholipid includes phosphatidic acid, lysophosphatidic acid, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, phosphatidyl.
- choline and phosphatidyl glycerol are also selected from the group.
- the fatty acid is selected from the group consisting of linoleic acid, oleic acid, linolenic acid, arachidonic acid, myristic acid, noremitoylic acid, palmitic acid, and stearic acid. Linoleic acid, linolenic acid and arachidonic acid, which are essential nutritional fatty acids, are particularly preferred.
- the culture medium additive kit of the present invention may further comprise cholesterol.
- the culture medium additive kit according to the present invention may further include a lipid acidification inhibitor.
- the lipid antioxidant is DL-hytocopherol acetate (vitamin E)! /.
- the culture medium additive kit of the present invention may further include a surfactant.
- the surfactant is preferably Pluronic F-68 or Tween 80, but may be other surfactants.
- the culture medium additive kit according to the present invention may further comprise insulin, transferrin, and selenate.
- the culture medium additive kit according to the present invention may further comprise dexamethasone or another darcocorticoid.
- the culture method according to the present invention comprises TGF- ⁇ , PDGF, at least one phospholipid, at least one fatty acid, and EGF, CTG in order to continuously subculture mouse fibroblasts. It includes the step of simultaneously adding at least two factors selected from the group consisting of F, VEGF, and ascorbic acid compound to the basal medium.
- the culture method according to the present invention may further include a step of adding FGF and Z or HGF to the basal medium.
- the medium additive according to the present invention comprises PDGF, at least one phospholipid, at least one fatty acid, and EGF, CTGF, VEGF, and ascorbic acid for the continuous passage culture of Chinese nomstar ovary-derived cells. It is characterized by containing at least two factors selected from the group consisting of compounds.
- the culture medium additive of the present invention may further contain at least one factor selected from the group consisting of FGF, TGF- ⁇ , and HGF.
- the phospholipid comprises phosphatidic acid, lysophosphatidic acid, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine, and Phosphatidylglycerol is also preferably selected from the group consisting of:
- the fatty acid is selected from the group consisting of linoleic acid, oleic acid, linolenic acid, arachidonic acid, myristic acid, palmitoyl acid, normitic acid, and stearic acid power. Particularly preferred are the essential nutritional fatty acids linoleic acid, linolenic acid and arachidonic acid.
- the culture medium additive of the present invention may further contain cholesterol.
- the culture medium additive of the present invention may further contain a lipid antioxidant.
- the lipid antioxidant is preferably DL-a-tocopherol acetate (vitamin E).
- the culture medium additive of the present invention may further contain a surfactant.
- the surfactant is Pluronic F-68 or
- Tween 80 is preferred, but other surfactants may be used.
- the culture medium additive of the present invention may further contain insulin, transferrin, and selenate.
- the culture medium additive according to the present invention includes dexamethasone or other group.
- a lucocorticoid may further be contained.
- the culture medium additive kit according to the present invention comprises PDGF, at least one phospholipid, at least one fatty acid, and EGF, CTGF, VEGF, and ascorbine for continuous subculture of Chinese hamster ovary-derived cells. Featuring at least two factors selected from the group consisting of acid compounds! /
- the culture medium additive kit according to the present invention may further include at least one factor selected from the group consisting of FGF, TGF- ⁇ , and HGF force.
- the phospholipid comprises phosphatidic acid, lysophosphatidic acid, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, phosphatidyl.
- choline and phosphatidyl glycerol are also selected from the group.
- the fatty acid is selected from the group consisting of linoleic acid, oleic acid, linolenic acid, arachidonic acid, myristic acid, noremitoylic acid, palmitic acid, and stearic acid. Linoleic acid, linolenic acid and arachidonic acid, which are essential nutritional fatty acids, are particularly preferred.
- the culture medium additive kit of the present invention may further comprise cholesterol.
- the culture medium additive kit according to the present invention may further comprise a lipid acidification inhibitor.
- the lipid antioxidant is preferably DL-a-tocopherol acetate (vitamin E)! /.
- the culture medium additive kit of the present invention may further comprise a surfactant.
- the surfactant is preferably Pluronic F-68 or Tween 80, but may be other surfactants.
- the culture medium additive kit of the present invention may further comprise insulin, transferrin, and selenate.
- the culture medium additive kit according to the present invention may further comprise dexamethasone or another darcocorticoid.
- the culture method according to the present invention comprises PDGF, at least one phospholipid, at least one fatty acid, and EG in order to continuously subculture Chinese, Muster ovary-derived cells. It includes the step of simultaneously adding at least two factors selected from the group consisting of F, CTGF, VEGF and ascorbic acid compound to the basal medium.
- the culture method according to the present invention may further include a step of adding at least one factor selected from the group consisting of FGF, TGF- ⁇ , and HGF to the basal medium.
- the medium additive according to the present invention comprises FGF, at least one phospholipid, at least one fatty acid, and EGF, CTGF, VEGF, and ascorbic acid for continuous subculture of human skin-derived fibroblasts. It is characterized by having at least two factors selected from the group consisting of
- the culture medium additive of the present invention may further contain at least one factor selected from the group consisting of TGF- ⁇ , HGF and PDGF power.
- the phospholipid includes phosphatidic acid, lysophosphatidic acid, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine, and Phosphatidylglycerol is also preferably selected from the group consisting of:
- the fatty acid is selected from the group consisting of linoleic acid, oleic acid, linolenic acid, arachidonic acid, myristic acid, palmitoyl acid, normitic acid, and stearic acid power. Particularly preferred are the essential nutritional fatty acids linoleic acid, linolenic acid and arachidonic acid.
- the culture medium additive of the present invention may further contain cholesterol.
- the culture medium additive of the present invention may further contain a lipid antioxidant.
- the lipid antioxidant is preferably DL-a-tocopherol acetate (vitamin E).
- the culture medium additive of the present invention may further contain a surfactant.
- the surfactant is Pluronic F-68 or
- Tween 80 is preferred, but other surfactants may be used.
- the culture medium additive of the present invention may further contain insulin, transferrin, and selenate.
- the culture medium additive according to the present invention includes dexamethasone or other group.
- a lucocorticoid may further be contained.
- the culture medium additive kit according to the present invention comprises FGF, at least one phospholipid, at least one fatty acid, and EGF, C for continuous subculture of human skin-derived fibroblasts.
- TGF TGF
- VEGF vascular endothelial growth factor
- ascorbic acid compounds TGF, VEGF and ascorbic acid compounds.
- the culture medium additive kit according to the present invention may further include at least one factor selected from the group consisting of TGF- ⁇ , HGF, and PDGF power.
- the phospholipid includes phosphatidic acid, lysophosphatidic acid, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, phosphatidyl.
- choline and phosphatidyl glycerol are also selected from the group.
- the fatty acid is selected from the group consisting of linoleic acid, oleic acid, linolenic acid, arachidonic acid, myristic acid, noremitoylic acid, palmitic acid, and stearic acid. Linoleic acid, linolenic acid and arachidonic acid, which are essential nutritional fatty acids, are particularly preferred.
- the culture medium additive kit of the present invention may further comprise cholesterol.
- the culture medium additive kit according to the present invention may further comprise a lipid acidification inhibitor.
- the lipid antioxidant is preferably DL-hytocopherol acetate (vitamin koji)! /.
- the culture medium additive kit of the present invention may further include a surfactant.
- the surfactant is preferably Pluronic F-68 or Tween 80, but may be other surfactants.
- the culture medium additive kit of the present invention may further comprise insulin, transferrin, and selenate.
- the culture medium additive kit of the present invention may further comprise dexamethasone or another darcocorticoid.
- the culture method according to the present invention comprises FGF, at least one phospholipid, at least one fatty acid, and EGF, CTGF, VE, for continuous subculture of human skin-derived fibroblasts. It includes the step of simultaneously adding at least two factors selected from the group consisting of GF and ascorbic acid compound to the basic medium.
- the culture method according to the present invention may further include a step of adding at least one factor selected from the group consisting of TGF- ⁇ , HGF and PDGF to the basal medium.
- FIG. 1 A graph showing the effect of addition of a serum replacement substance to a serum-free medium on the proliferation of human mesenchymal stem cells (MSC).
- FIG. 2 shows morphological changes of human mesenchymal stem cells (MSC) cultured in serum-free medium.
- FIG. 3 shows the evaluation of bone differentiation ability of human mesenchymal stem cells (MSC) cultured in serum-free medium.
- FIG. 4 is a diagram showing the evaluation of adipogenic potential of human mesenchymal stem cells (MSC) cultured in a serum-free medium.
- FIG. 5 shows the evaluation of the cartilage differentiation ability of human mesenchymal stem cells (MSC) cultured in serum-free medium.
- FIG. 6 is a graph showing the evaluation of cartilage differentiation ability of human mesenchymal stem cells (MSC) cultured in serum-free medium.
- FIG. 7 is a graph showing the effect of adding a serum replacement substance to a serum-free medium on the proliferation of human mesenchymal stem cells (MSC).
- FIG. 8 is a graph showing the effect of adding a serum replacement substance to a serum-free medium on the proliferation of human mesenchymal stem cells (MSC).
- FIG. 9 is a graph showing the effect of addition of a serum replacement substance to a serum-free medium on the proliferation of human mesenchymal stem cells (MSC).
- FIG. 10 is a graph showing the effect on the growth of C2C12 cells by adding a serum replacement substance to a serum-free medium.
- FIG. 11 is a graph showing the influence of human mesenchymal stem cells (MSCs) on the cell proliferation signal transduction system by adding a serum replacement substance to a serum-free medium.
- MSCs human mesenchymal stem cells
- FIG. 12 shows the effect of human mesenchymal stem cells (MSCs) on the cell proliferation signaling system by the addition of a serum replacement substance to a serum-free medium.
- FIG. 13 is a diagram showing a serum replacement substance added to a serum-free medium of mesenchymal stem cells (MSC).
- MSC mesenchymal stem cells
- FIG. 14 is a view showing a serum replacement substance added to a serum-free medium of C2C 12 cells.
- FIG. 15 (a) shows the effect of addition of a serum replacement substance on a serum-free medium on the proliferation of human mesenchymal stem cells (MSC).
- FIG. 15 (b) shows the effect on the proliferation of human mesenchymal stem cells (MSCs) by adding a serum replacement substance to a serum-free medium.
- FIG. 16 (a) shows the effect of addition of a serum replacement substance to a serum-free medium on the proliferation of primary human mesenchymal stem cells (MSC).
- FIG. 16 (b) shows the effect of the addition of a serum replacement substance on serum-free medium on the proliferation of primary human mesenchymal stem cells (MSC).
- FIG. 17 (a) shows the effect on the growth of 10T1Z2 cells by adding a serum substitute to serum-free medium.
- FIG. 17 (b) shows the effect on the growth of CHO cells due to the addition of a serum replacement substance to a serum-free medium.
- FIG. 17 (c) is a graph showing the effect of adding a serum replacement substance to a serum-free medium on the proliferation of human Hiff fibroblasts (Fibroblast).
- various peptide hormones, growth factors, lipids, and the like are used for culturing cells in a medium (serum-free medium) without serum without losing growth.
- the medium supplemented with these serum substitute components does not necessarily have a sufficient cell growth promoting effect as compared with the serum-containing medium. Therefore, the present inventors examined a human mesenchymal stem cell culture method comparable to the conventional culture method using a 10% serum-containing medium even under conditions of low serum (0.5 to 2%). did.
- animal cells can be grown in large quantities in a culture system under low serum conditions or serum-free conditions.
- cells having regenerative medical uses such as mesenchymal stem cells
- cell proliferation not only in a test tube but also on an industrial scale can be realized, and the production cost can be greatly reduced.
- the present invention provides a medium additive for serum-free culture of animal cells.
- the culture medium additive according to the present invention contains at least three growth factors selected from the group consisting of FGF, PDGF, TGF- ⁇ and HGF, and at least one phospholipid.
- Examples of the phospholipid contained in the culture medium additive according to the present invention include phosphatidic acid, lysophosphatidic acid, phosphatidylinositol, phosphatidylserine, and phosphatidylethanolamine.
- Phosphatidylcholine, phosphatidylglycerol, and the like, and the culture medium additive according to the present invention may contain these phospholipids alone or in combination.
- the culture medium additive according to the present invention contains phosphatidic acid and phosphatidylcholine in combination.
- these phospholipids may be derived from animals or plants.
- the culture medium additive according to the present invention preferably further contains at least one fatty acid.
- the fatty acid contained in the medium additive according to the present embodiment include linoleic acid, oleic acid, linolenic acid, arachidonic acid, myristic acid, normitoyl acid, palmitic acid, stearin, and the like.
- the culture medium additive according to this embodiment may contain these fatty acids alone or in combination!
- the culture medium additive according to the present embodiment may further contain cholesterol in addition to the fatty acid.
- FGF is fibroblast growth factor (FGF).
- Growth factor is also a growth factor of choice and is preferably FGF-2 (bFGF), although other FGF family efforts such as FGF-1 may also be selected.
- bFGF FGF-2
- PDGF is intended to be a growth factor selected from the platelet-derived growth factor (PDGF) family and is PDG F—BB or PDGF—AB. It is preferable.
- TGF- ⁇ is intended to be a growth factor for which the transforming growth factor- ⁇ (TGF- ⁇ ) family is also selected, and TGF- ⁇
- TGF- ⁇ 3 is preferred, but may be selected from other TGF- ⁇ families.
- the culture medium additive according to the present invention includes epidermal growth factor (EGF), connective tissue growth factor (CTGF), vascular endothelial growth factor (VEGF). And at least two factors selected from the group consisting of ascorbic acid compounds.
- EGF epidermal growth factor
- CGF connective tissue growth factor
- VEGF vascular endothelial growth factor
- Ascorbic acid compound as used herein is intended to be ascorbic acid (vitamin C) or ascorbic acid diphosphate, or a similar compound.
- the growth factor contained in the culture medium additive of the present invention may be natural or produced by genetic recombination.
- the culture medium additive according to the present invention preferably contains a lipid antioxidant.
- the lipid antioxidant contained in the medium additive according to the present embodiment may be DL-a-tocopherol acetate (vitamin E).
- the culture medium additive according to the present invention may further contain a surfactant.
- the surfactant contained in the medium additive according to this embodiment may be Plur onic F-68 or Tween 80.
- the culture medium additive of the present invention may further contain insulin, transferrin, and selenate.
- insulin may be an insulin-like growth factor, may be derived from natural cells, or may be produced by genetic recombination.
- the culture medium additive according to the present invention may further contain dexamethasone or other darcocorticoid.
- the present invention provides a medium additive kit for serum-free culture of animal cells.
- the culture medium additive kit according to the present invention comprises at least three growth factors selected from the group consisting of FGF, PDGF, TGF- ⁇ and HGF, and at least one phospholipid.
- the culture medium additive kit according to the present invention comprises at least three growth factors selected from the group consisting of FGF, PDGF, TGF- ⁇ and HGF and at least one phospholipid in the same container. These components may be provided separately.
- the culture medium additive kit according to the present invention preferably further comprises at least one fatty acid.
- the culture medium additive kit according to the present embodiment comprises at least three growth factors selected from the group consisting of FG F, PDGF, TGF- ⁇ , and HGF, at least one phospholipid, and at least one fatty acid. Even if it is provided in the same container, these components may be provided separately.
- composition is a form in which each main component is contained in one substance, and a “kit” contains at least one of each main ingredient in another substance.
- the present invention provides a culture medium for serum-free culture of animal cells.
- the culture medium according to the present invention contains at least three growth factors selected from the group consisting of FGF, PDGF, TGF- ⁇ and HGF, and at least one phospholipid.
- the culture medium according to the present invention only needs to contain at least three growth factors selected from the group consisting of FGF, PDGF, TGF- ⁇ and HGF, and at least one phospholipid. May be added to the basal medium simultaneously or separately. That is, the culture medium according to the present invention includes the components contained in the above-described medium additive or the medium additive calorie kit, and contains the above components.
- the culture medium according to the present invention preferably further contains at least one fatty acid.
- the medium additive kit according to the present embodiment comprises at least three growth factors selected from the group consisting of FGF, PDGF, TGF- ⁇ and HGF, and a small amount. These ingredients, as long as they contain at least one phospholipid and at least one fatty acid, may be added simultaneously or separately to the basal medium. That is, the culture medium according to the present invention may be contained in the above-described medium additive or included in the medium additive kit, and may contain the component. .
- the basal medium for constituting the culture medium according to the present invention is not particularly limited as long as it is a well-known animal cell medium in the art, and preferred basal media include, for example, Ham's F12 medium, Examples include DMEM medium, RPMI-1640 medium, and MCDB medium. These basal media may be used alone or in combination.
- the basal medium for constituting the culture medium according to the present invention is preferably a medium in which MCDB and DMEM are mixed at a ratio of 1: 1.
- the present invention provides a culture method for serum-free culture of animal cells.
- the culture method according to the present invention comprises animal cells in a culture medium containing at least three growth factors selected from the group consisting of FGF, PDGF, TGF- ⁇ and HGF, and at least one phospholipid.
- the step of culturing The culture medium may further contain at least one fatty acid. That is, the culture method according to the present invention can be obtained by using the culture medium described above when culturing animal cells.
- the culture method according to the present invention comprises at least three growth factors selected from the group consisting of FGF, PDGF, TGF- ⁇ and HGF, and at least one phospholipid in a basal medium. You may include the process of adding simultaneously.
- the basal medium is not particularly limited as long as it is a well-known animal cell medium in the art as described above.
- animal cells can be grown while maintaining their characteristics at a rate equal to or higher than that when cultured in a 10% serum-containing medium even in a serum-free medium.
- stem cells particularly human mesenchymal stem cells
- they can be continuously subcultured while maintaining their characteristics (bone differentiation ability, fat content, etc.) at a high level.
- the serum-free medium according to the present invention when used, the number of cells can be increased at least 10,000 times or more at the start of the culture.
- this departure Akira also provides a culture medium additive, a culture medium additive kit, a culture medium, and a culture method for continuously subculturing stem cells.
- the present invention provides a medium additive for continuously subculturing stem cells.
- the culture medium additive according to the present invention contains at least three growth factors selected from the group consisting of FGF, PDGF, TGF- ⁇ and HGF power, and at least one phospholipid.
- the culture medium additive according to the present invention preferably further contains at least one fatty acid.
- the present invention provides a culture medium additive kit for continuously subculturing stem cells.
- the culture medium additive kit according to the present invention contains at least three growth factors selected from the group consisting of FGF, PDGF, TGF- ⁇ and HGF, and at least one phospholipid.
- the culture medium additive kit according to the present invention preferably further contains at least one fatty acid.
- the present invention provides a culture medium for continuously subculturing stem cells.
- the culture medium according to the present invention contains at least three growth factors selected from the group consisting of FGF, PDGF, TGF- ⁇ and HGF, and at least one phospholipid.
- the culture medium according to the present invention further comprises at least one fatty acid.
- the present invention provides a culture method for serially culturing stem cells.
- the culture method according to the present invention comprises at least three growth factors selected from the group consisting of FGF, PDGF, TGF- ⁇ , and HGF, and at least one phospholipid in a culture medium. Including culturing animal cells.
- the culture medium may further contain at least one fatty acid. That is, it can be said that the culture method according to the present invention may use the culture medium described above when continuously subculturing stem cells.
- the present invention shows a stronger effect on undifferentiated cells such as stem cells, but loses a special dividing ability and is close to an undivided state. It is also very effective in culturing cells (eg, monkey kidney-derived COS cells) under serum-free conditions. That is, the cell that can be applied to the present invention is an undifferentiated cell that is preferable to an undifferentiated cell.
- undifferentiated cells such as stem cells
- culturing cells eg, monkey kidney-derived COS cells
- Bone marrow undifferentiated mesenchymal stem cells skeletal muscle stem cells, hematopoietic stem cells, neural stem cells, hepatic stem cells, fat, tissue stem cells, adipose precursor cells, vascular endothelial precursor cells, cartilage precursor cells, lymphoid precursor cells, They can be stem cells such as NK progenitor cells, embryonic stem cells, or fibroblasts, and mesenchymal stem cells are more preferred.
- the culture method to be noted when using these cells may follow a known culture method for each cell.
- FIG. 13 shows components in the medium used for culturing mesenchymal stem cells (MSC)
- FIG. 14 shows components in the medium used for culturing C2C12 cells. Note that these components may have higher concentrations than the upper limits of the values shown in FIG. 13 and FIG.
- Example 1 Bloodless culture of bone marrow-derived mesenchymal stem cells (MSC)]
- Mesenchymal stem cells derived from human iliac bone marrow (3rd pass: purchased from Bio—Whitterker (Walkersville, MD)) 3 times with serum-free DMEM medium, and the cells are placed on a 24-well plate. The cells were seeded at a density of Zcm2 and cultured at 37 ° C in a C02 incubator in the presence of 5% C02.
- DMEMZMCDB 1: 1 as the basal medium was added to the following additives and used for culture:
- FBS urchin fetal serum
- Table 1 shows the composition of the basal medium of the serum-free medium.
- the company components shown in Fig. 13 and Fig. 14 were also purchased for the various components added to the medium.
- the MCDB201 (Sigma: M-67 70) medium which is the basal medium, was developed for clonal expansion of chick avian embryo fibroblasts and contains complete trace elements!
- MCDB201ZDMEM (1: 1) compared to the conventional basal medium DMEM or DMEMZHam's F-12 of mesenchymal stem cells, the optimal proliferation promotion of mesenchymal stem cells was shown (not shown) ).
- Linoleic Acid 0.000042 0.000042
- the basic medium (medium 3) comprises a growth factor group (FGF, HGF, TGF- ⁇ , PDGF) and a fatty acid complex (arachidonic acid, retinoic acid, linolenic acid, oleic acid, linolenic acid, myristic acid).
- FGF growth factor group
- HGF growth factor group
- TGF- ⁇ TGF- ⁇
- PDGF vascular endothelial growth factor group
- a fatty acid complex arachidonic acid, retinoic acid, linolenic acid, oleic acid, linolenic acid, myristic acid.
- insulin, transferrin, selenate such as sodium selenate
- SSA dexamethasone
- BSA ushi serum albumin
- vitamin E as a lipid acidification inhibitor
- Pluroni c F-68 and Tween 80 surfactants.
- the basic medium (medium 3) according to the present invention showed a cell growth effect equivalent to that of a conventional 10% FBS-containing medium when 2% FBS was added (not shown).
- this basal medium was used under serum-free conditions, it was inferior to the medium containing 10% FBS but showed an excellent cell proliferation effect (about 45% of the cell proliferation level in the medium containing 10% FBS: Fig. 1).
- phospholipids derived from animals phosphatidic acid (PA), phosphatidylcholine (PC)
- PA phosphatidic acid
- PC phosphatidylcholine
- the cell proliferation effect was shown (about 8.5 times the cell proliferation level in a medium containing 10% FBS: Fig. 1).
- Lecithin from Soybean, Wako (120-00832) 200mg was added to Chloroform. After drying this using a nitrogen gas distillation method, 20 ml of PBS (—) was added. This solution is sonicated for 15 minutes at room temperature. The mixture was equilibrated by sonication, further sonicated for 30 seconds to 2 minutes on ice under nitrogen gas, and then centrifuged (2500 rpm) at room temperature for 5 minutes. If there was a precipitate, it was further sonicated on ice for 5 minutes, and then centrifuged (2500 rpm) at room temperature for 5 minutes. The supernatant collected after repeating this process was filtered through a 0.45 m filter, sealed with nitrogen gas, and stored refrigerated in the dark.
- medium 5 showed an excellent cell growth effect equivalent to that of the basic medium (medium 3) even in the absence of serum (the cell growth level in the medium containing 10% FBS). About 40%: Figure 1).
- FIG. 1 The morphology of mesenchymal stem cells cultured in the serum-free medium used in this example is shown in FIG.
- FIG. 2 cells cultured in serum-free medium (passage 3) show a spindle-shaped shape typical of mesenchymal stem cells compared to cells cultured in medium containing 10% FBS. It was. Cell growth was reduced in serum-free medium except for TGF- ⁇ or HGF alone.
- the third-generation human iliac bone subcultured continuously in serum-free medium After collecting the mesenchymal stem cells derived from it, osteogenesis induction medium (containing ⁇ - ⁇ , 10% FBS, ⁇ Dex amethasone, lOmM ⁇ -Lrlycerophosphoric acid, and 50 gz ml L-As corbie acid 2-phosphate).
- osteogenesis induction medium containing ⁇ - ⁇ , 10% FBS, ⁇ Dex amethasone, lOmM ⁇ -Lrlycerophosphoric acid, and 50 gz ml L-As corbie acid 2-phosphate.
- Mesenchymal stem cells in bone differentiation-inducing medium were cultured at 37 ° C in the presence of 5% carbon dioxide and replaced with the same medium induction medium every 2-3 days for a total of 28 days.
- Cell layers differentiated from bone and calcified were stained with alizarin red. The results are shown in Figure 3.
- alizarin red which shows calcification characteristic of osteoblasts as a result of culturing mesenchymal stem cells (passage 4) cultured in serum-free medium for 28 days in bone differentiation-inducing medium. , And calcium deposits were observed.
- mesenchymal stem cells cultured in the serum-free medium maintained high bone differentiation ability (calcification ability). In particular, the highest bone function was observed with the addition of two phospholipids.
- the third-generation human iliac bone subcultured continuously in serum-free medium Proliferate mesenchymal stem cells derived to confluence, disperse with trypsin, and collect , Transferred to adipogenic differentiation medium (consisting of high glucose-containing DMEM, 10 / z gZml Insulin, 0.2 mM Indometnacm, 1 M Dexamethasone, 0.5 mM 3-Isobutyl-1, 1-methnyl xanthine, and 10% FBS).
- adipogenic differentiation medium consisting of high glucose-containing DMEM, 10 / z gZml Insulin, 0.2 mM Indometnacm, 1 M Dexamethasone, 0.5 mM 3-Isobutyl-1, 1-methnyl xanthine, and 10% FBS.
- Mesenchymal stem cells in adipose differentiation-inducing medium were cultured at 37 ° C in the presence of 5% carbon dioxide gas, and replaced with the same fractionation-inducing medium every 2-3 days for a total of 28 days. . Adipose differentiation was assessed by staining the cells with Oil Red O. The results are shown in Fig. 4.
- mesenchymal stem cells (passage 4) cultured in serum-free medium were cultured for 28 days in an adipogenic medium, and as a result, stained with oil red O indicating fat. .
- all the mesenchymal stem cells cultured in the serum-free medium maintained a high fat content.
- chondrocyte induction medium high glucose a-MEM, lOng / mlT GF— j8 ⁇
- ITS—Puffus (6.25 gZml Transf errin, 6.25 ⁇ gZ ml Insulin, 6.25 ngZ ml selenate, 5.33 ⁇ gZ ml linolei c acid, 1.25 mgZml ushi serum albumin: BSA). Moved to).
- 200,000 cells were placed in a centrifuge tube (for 15 ml) and incubated with 0.5-ml of the following medium.
- mesenchymal stem cells were transferred to a control medium in which TGF- ⁇ was removed from the cartilage differentiation induction medium.
- GAGs in the pellets after culturing were quantified using a kit for quantification of glycosaminoglycan (GAG) sulfate (manufactured by Biocolor). The results are shown in FIG. The amount of GAG was normalized according to the DNA content of the cells.
- the cartilage-separated cells in the cartilage induction medium after culture were stained with toluidine blue.
- Fig. 6 The results are shown in Fig. 6.
- Fig. 5 mesenchymal stem cells cultured in a serum-free medium and a medium containing 10% FBS were cultured in a cartilage differentiation induction medium for 21 days.
- Cells (passage 5) showed significantly higher amounts of GAG compared to mesenchymal stem cells cultured in medium containing 10% FBS (p ⁇ 0.01).
- no increase in the amount of GAG was observed in any medium. Indicates the average value SD of the experiment conducted in triplicate).
- mesenchymal stem cells cultured in a serum-free medium and a medium containing 10% FBS were cultured in a cartilage differentiation-inducing medium for 21 days.
- mesenchymal stem cells cultured in a serum-free medium Compared to mesenchymal stem cells cultured in a medium containing 10% FBS (passage 5), matrix staining was observed with a significantly higher level of toluidine blue staining.
- Example 3 Effect of growth factors in serum-free culture of bone marrow-derived mesenchymal stem cells
- Human iliac bone marrow-derived mesenchymal stem cells (3rd generation) contain no serum! /, DMEM medium After washing 3 times with, cells are seeded on a 24-well plate at a density of 5000 Zcm2, 5% CO
- the cells were cultured at 37 ° C in a C02 incubator in the presence of 2.
- DMEMZMCDB 1: 1 as the basal medium was added to the following additives and used for culture:
- mesenchymal stem cells cultured in a serum-free medium (medium 3-8, medium 4, medium 41, or medium 5) are compared with those cultured in medium 3,
- the cell growth rate on the 8th day of culture was enhanced (the value indicates the average value SD of the experiment conducted in triplicate). In particular, this effect was remarkable when cultured in the medium 4 or the medium 4-1. From this, it was found that EGF, VC and high concentrations of VE, which are not only phospholipids, are also effective in promoting the proliferation of mesenchymal stem cells.
- TGF- ⁇ or HGF was removed from the basic medium (medium 3)
- the cell proliferation rate of the mesenchymal stem cells was significantly reduced. This indicates that ⁇ GF- ⁇ and HGF are essential for serum-free culture of mesenchymal stem cells.
- a medium (medium 5) containing a lipid mixture mainly composed of plant-derived lecithin (corresponding to animal-derived phosphatidylcholine (PC)) is also mainly composed of many fatty acids. It was found to be useful for serum-free culturing of mesenchymal stem cells in the same manner as the medium containing the lipid mixture (Medium 4) (Fig. 7).
- mesenchymal stem cells cultured in serum-free medium had an increased cell growth rate on day 8 of culture compared to medium 3 (numerical values) Indicates the average value SD of the experiment conducted in triplicate).
- Mesenchymal stem cells derived from human iliac bone marrow (3rd generation) were washed 3 times with serum-free DMEM medium, and the cells were seeded on a 24-well plate at a density of 5000 Zcm2, 5% CO
- the cells were cultured at 37 ° C in a C02 incubator in the presence of 2.
- DMEMZMCDB 1: 1 as basal medium was added to the following additives and used for culture:
- mesenchymal stem cells cultured in serum-free medium showed the same cell growth rate as that cultured in medium 3 (the values are in triplicate). (Indicates the mean value SD of the experiment conducted in).
- mesenchymal stem cells cultured in a medium containing a phospholipid lecithin derived from a plant and a medium containing retinoic acid are the same as those cultured in a basic medium (medium 3). The growth rate was shown.
- Mouse mesenchymal stem cells C2C12 cells (or mouse chondrocyte line ATDC5 or monkey kidney-derived undifferentiated cell line COS 7 cells), DMEM containing 10% urine fetal serum, 100 units Zml penicillin, and 100 ⁇ g Zml streptomycin The cells were cultured at 37 ° C. in a C02 incubator in the presence of 5% C02 on a 10 cm plate containing the medium. Cells were washed twice with PBS and detached from the plate by incubating for 2 minutes in PBS containing 0.05% trypsin and 0.2 mM EDTA, and plant-derived try psin inhibitor (Sigma : T6522) and resuspended. After washing the cells three times in serum-free DMEM medium, the number of cells was counted with a Coulter counter (Z1 single, Coulter). The result is shown in FIG.
- the resuspended cells were replated at a density of 5000 Zcm2 in 24-well plates using the following different media conditions.
- the cell line C2C 12 cells cultured in serum-free medium showed much better cell growth than normal 10% FBS-containing medium (medium 2).
- the growth ability of this cell line was markedly reduced when a medium from which only the medium strength HGF was removed (medium 43) was used (the figure shows the mean value SD of the experiment carried out in triplicate).
- the serum-free medium (medium 42) can be used even if this serum-free medium (medium 42) is used. )
- the effect of promoting cell proliferation to such an extent was not possible. That is, this serum-free medium (medium 5) was shown to be more effective with undifferentiated cells.
- the serum-free medium of the present invention is also effective for culturing cells (for example, monkey kidney-derived COS7 cells) under serum-free conditions that have lost their special differentiation ability and are 10% A growth promoting effect comparable to that of the FBS-containing medium (medium 2) was obtained.
- the cultured cells were washed twice with PBS and further cultured for 16 hours in a serum-free medium containing 25 mg / ml BSA (usi serum albumin).
- the cultured cells are then treated with each growth factor (E: EGF, F: FGF, G: PDGF, H: HGF, I: Insulin, J: TGF- ⁇ ), Dexamethasone (D), Transferrin (T), and fatty acids.
- FIG. 11 shows protein fractions when cells were stimulated with growth factors (E to J), Dexamethasone (D), and Transferrin (T). As shown in Figure 11, compared to control cells (stimulated, non-viable cells), by EGF ( ⁇ ), FGF (F), PDGF (G), Insulin (1), and HGF (H) It was shown that ErklZ2 is phosphorylated in stimulated cells. In particular, in cells stimulated with HGF, phosphorylation of ErklZ2 was promoted in a concentration-dependent manner, and phosphorylation of Akt was also promoted.
- EGF growth factor
- D Dexamethasone
- T Transferrin
- Figure 12 shows protein fractions when cells were stimulated with fatty acid-related factors (A1-A7).
- A1-A7 fatty acid-related factors
- FIG. 12 shows protein fractions when cells were stimulated with fatty acid-related factors (A1-A7).
- the phosphorylation of ErklZ2 and Akt was strongly promoted in cells stimulated with phosphatidic acid (A6) compared to control cells (unstimulated cells).
- ErklZ2 phosphorylation was promoted in cells stimulated by Arachidonic acid (Al), Linoleic acid (A2), L inolenic acid (A3), Oleic acid (A4), and Phosphatidyl choline (A7).
- these fatty acid-related factors have been shown to activate the cell proliferation signaling system as a growth factor that simply supplies energy and membrane components to cultured cells.
- Example 8 Action of additional basic factors in serum-free culture of human bone marrow-derived mesenchymal stem cells
- lithium chloride (LiCl) can promote the proliferation of human mesenchymal stem cells by activating the wingles s / int (wnt) signaling pathway.
- ES cells embryonic stem cells
- L-glutthione human kidney as an antioxidant (reducing agent). Therefore, in order to examine the effects on the proliferation of mesenchymal stem cells of lithium chloride (Li C1) and L glutathione, the following serum-free medium supplemented with lithium chloride or L-glutthione was used for humans.
- Mesenchymal stem cells were cultured.
- the cultured cells were washed twice with PBS (-) and dispersed by incubating in PBS containing 0.05% trypsin and 0.2 mM EDTA for 2 minutes. It was resuspended with Trypsin inhibitor (Sigma: T6522) derived from a plant not containing sucrose. Furthermore, the cultured cells were washed three times with serum-free DMEM medium, and the number of cells was counted with a Coulter counter (Z1 single, Coulter). The resuspended cells were then replated at a density of 5000 Zcm 2 on 96-well plates using the following media.
- Trypsin inhibitor Sigma: T6522
- the proliferation ability of the cells cultured in the culture medium 4-4 compared with the proliferation ability of the cells cultured in the culture medium 4-2 and the culture medium 2 was as follows. Remarkably high strength (values indicate the average value of the experiments conducted in triplicate, SD).
- the growth ability of the cells cultured in the culture medium 4-5 was as follows. Remarkably high strength (values indicate the average value of the experiments conducted in triplicate, SD).
- Bone marrow fluid from the iliac was collected from the patient.
- the mononuclear cell fraction (including MSC) was separated from the collected iliac bone marrow fluid by density gradient centrifugation.
- 24 well plates were seeded at a density of IX 10 6 (nucleated) cells Zcm 2 and cultured at 37 ° C in a CO incubator in the presence of 5% CO. .
- DMEMZMCDB 1: 1 as a basal medium with the following additives and used for culture (Medium 1) No addition
- medium 3 and medium 10 exhibiting a high cell proliferation effect in subculture had a low ability to promote cell proliferation in the primary culture of bone marrow-derived mesenchymal stem cells. This is probably because it affects the proliferation of many hematopoietic cells other than mesenchymal stem cells contained in the bone marrow mononuclear cell fraction. These non-adherent hematopoietic cells are removed every time the medium is changed, and hardly exist after one subculture. However, when 1 to 3 growth factors contained in medium 10 were removed (medium 10-1 to medium 10-7), the proliferation ability of mesenchymal stem cells under serum-free conditions was improved. For example, in culture medium 10-1, the proliferation of cultured cells was promoted.
- culture medium 10-4 clearly improved the proliferation ability of cultured cells.
- culture medium 10-7 the proliferative capacity of cultured cells is significantly increased. (The figure shows the average value of the experiment conducted in triplicate.) Thus, it was shown that the optimal composition of the serum replacement substance changes when many cells other than mesenchymal stem cells, such as hematopoietic cells, are present in the serum-free medium.
- mouse mesenchymal cell line 10T1Z2 (provided by RIKEN BioResource Center)
- Chinese ovum and Muster ovary Cell lines
- CHO cells (provided by RIKEN Bioresource Center)
- human Hiff fibroblasts (Fibroblast) (provided by Human Science Research Resource Bank) were cultured in the following media.
- 10T1Z2 cells, CHO cells, and Fibroblast were placed in a 10 cm plate containing DMEM medium containing 10% ushi fetal serum, 100 units Zml penicillin, and 100 ⁇ g Zml streptomycin in a CO incubator in the presence of 5% CO. Incubate at 37 ° C
- Subconfluent cells were washed twice with PBS (—) and detached from the plate by incubating for 2 minutes in PBS containing 0.05% trypsin and 0.2 mM EDTA. .
- the detached cells were resuspended with plant-derived Trypsin inhibit or (Sigma: T6522) without serum.
- Cells in DMEM medium without serum 3 After washing twice, the number of cells was counted with a Coulter counter (Z1 single, manufactured by Coulter).
- the cell line 10T1Z2 cells cultured in medium 10-5 showed almost the same cell proliferating ability as the cell line 10T1Z2 cells cultured in medium 2 (the values are in triplicate).
- the mean value of the experiment conducted at is shown as SD.
- CHO cells cultured in medium 10-7 showed effective cell growth ability (the figures show the mean value SD of the experiment conducted in triplicate). ).
- the growth ability of 1:01) 1 & st cultured in medium 10-8 compared to the growth capacity of Fibroblast cultured in medium 2 was 8 It was significantly higher on the first day (the figure shows the mean value of the experiment conducted in triplicate, SD).
- animal cells can be proliferated while maintaining their characteristics at a rate equivalent to or higher than that when cultured in a medium containing 10% serum even in a serum-free medium.
- a medium containing 10% serum even in a serum-free medium.
- human mesenchymal stem cells can be continuously subcultured while maintaining their characteristics (bone differentiation ability, fat content ability, etc.) at a high level.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20070706579 EP1988159B1 (en) | 2006-01-13 | 2007-01-11 | Additive for culture medium for use in serum-free culture of animal cell, kit, and use of the additive or kit |
KR1020087019812A KR101107835B1 (ko) | 2006-01-13 | 2007-01-11 | 동물 세포의 무혈청 배양에 사용하기 위한 배양 배지 첨가물, 키트 및 이의 용도 |
JP2007553929A JP4385076B2 (ja) | 2006-01-13 | 2007-01-11 | 動物細胞を無血清培養するための培地用添加剤、キット及びこれらの利用 |
US12/160,481 US9074176B2 (en) | 2006-01-13 | 2007-01-11 | Culture medium additive for use in serum-free culturing of animal cell, kit and use thereof |
AU2007205522A AU2007205522B2 (en) | 2006-01-13 | 2007-01-11 | Additive for culture medium for use in serum-free culture of animal cell, kit, and use of the additive or kit |
US14/725,073 US10184112B2 (en) | 2006-01-13 | 2015-05-29 | Culture medium additive for use in serum-free culturing of animal cell, kit and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-006706 | 2006-01-13 | ||
JP2006006706 | 2006-01-13 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/160,481 A-371-Of-International US9074176B2 (en) | 2006-01-13 | 2007-01-11 | Culture medium additive for use in serum-free culturing of animal cell, kit and use thereof |
US14/725,073 Division US10184112B2 (en) | 2006-01-13 | 2015-05-29 | Culture medium additive for use in serum-free culturing of animal cell, kit and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007080919A1 true WO2007080919A1 (ja) | 2007-07-19 |
Family
ID=38256324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/050232 WO2007080919A1 (ja) | 2006-01-13 | 2007-01-11 | 動物細胞を無血清培養するための培地用添加剤、キット及びこれらの利用 |
Country Status (6)
Country | Link |
---|---|
US (2) | US9074176B2 (ja) |
EP (1) | EP1988159B1 (ja) |
JP (1) | JP4385076B2 (ja) |
KR (1) | KR101107835B1 (ja) |
AU (1) | AU2007205522B2 (ja) |
WO (1) | WO2007080919A1 (ja) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009084662A1 (ja) | 2007-12-28 | 2009-07-09 | Fujirebio Inc. | 哺乳動物体細胞用培地及びそのための添加剤 |
WO2010055616A1 (ja) | 2008-11-11 | 2010-05-20 | 独立行政法人科学技術振興機構 | 分化誘導培地用添加剤およびその利用 |
WO2010095685A1 (ja) * | 2009-02-23 | 2010-08-26 | 富士レビオ株式会社 | 骨細胞への分化誘導培地及び方法 |
WO2011111787A1 (ja) | 2010-03-10 | 2011-09-15 | 株式会社ツーセル | 間葉系幹細胞を含む細胞製剤及びその製造方法 |
JP2012029684A (ja) * | 2010-06-30 | 2012-02-16 | Cell Aid Kenkyusho:Kk | 細胞の製造方法 |
JP2012506430A (ja) * | 2008-10-21 | 2012-03-15 | ザ ジェネラル ホスピタル コーポレイション | 細胞移植 |
JP2012524551A (ja) * | 2010-04-30 | 2012-10-18 | 中国科学院広州生物醫薬與健康研究院 | 培養培地添加物及びその応用 |
JP2014533113A (ja) * | 2011-11-11 | 2014-12-11 | エッセンシャル ファーマシューティカル エルエルシー | 血清代替物および不安定因子を備えるキット |
WO2015016357A1 (ja) * | 2013-08-01 | 2015-02-05 | 株式会社ツーセル | 軟骨損傷治療剤及びその製造方法 |
US9074176B2 (en) | 2006-01-13 | 2015-07-07 | Two Cells Co., Ltd. | Culture medium additive for use in serum-free culturing of animal cell, kit and use thereof |
WO2016136986A1 (ja) * | 2015-02-27 | 2016-09-01 | ロート製薬株式会社 | 間葉系幹細胞培養用培地、間葉系幹細胞の培養方法及び間葉系幹細胞 |
JP2017506511A (ja) * | 2014-02-14 | 2017-03-09 | ナショナル ユニバーシティー オブ アイルランド, ゴールウェイ | 無血清培地 |
JP2018506986A (ja) * | 2015-03-04 | 2018-03-15 | メゾブラスト・インターナショナル・エスアーエールエル | 間葉系幹細胞の細胞培養法 |
WO2018123968A1 (ja) | 2016-12-28 | 2018-07-05 | 株式会社ツーセル | 生体組織損傷の修復剤および当該修復剤の製造方法 |
US10184110B2 (en) | 2010-08-06 | 2019-01-22 | The General Hospital Corporation | System and apparatus for cell treatment |
JP2020162536A (ja) * | 2019-03-29 | 2020-10-08 | 興人ライフサイエンス株式会社 | 組み換えタンパク質産生増加のための培地用組成物 |
WO2021060460A1 (ja) | 2019-09-26 | 2021-04-01 | 株式会社ツーセル | 生体組織損傷の修復剤の製造方法および生体組織損傷の修復剤 |
CN112852719A (zh) * | 2019-11-12 | 2021-05-28 | 武汉济源高科技有限公司 | 一种临床级干细胞无血清培养基 |
WO2022049977A1 (ja) | 2020-09-03 | 2022-03-10 | 株式会社ツーセル | 中枢神経疾患の治療用組成物、中枢神経疾患の治療用組成物の製造方法および中枢神経疾患の治療用製剤の製造方法 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103068969A (zh) * | 2010-06-17 | 2013-04-24 | 思迪公司 | 化学成分确定的无血清细胞培养基 |
CN102349500B (zh) * | 2011-11-10 | 2013-04-03 | 成都清科生物科技有限公司 | 一种间充质干细胞自体保存液 |
CN104254602A (zh) * | 2012-04-24 | 2014-12-31 | 克瑞奥埃斯塔麦诺健康与技术股份有限公司 | 用于心脏组织保护的干细胞的组合物和方法 |
WO2014142751A1 (en) * | 2013-03-12 | 2014-09-18 | Agency For Science, Technology And Research | Method for culturing cells |
EP3098306A4 (en) | 2014-01-23 | 2017-07-26 | Nissan Chemical Industries, Ltd. | Undifferentiated maintenance culture material |
EP3208331A1 (en) * | 2016-02-17 | 2017-08-23 | PromoCell bioscience alive GmbH Biomedizinische Produkte | Chemically defined medium for the culture of cancer stem cell (csc) containing cell populations |
US20190255117A1 (en) | 2016-10-31 | 2019-08-22 | Biomimetics Sympathies Inc. | Synoviolin expression inhibitor containing mesenchymal stem cell or culture supernatant thereof |
CN110462025B (zh) * | 2017-01-23 | 2023-11-21 | 加拿大干细胞技术公司 | 增强干细胞存活和增殖的培养基和方法 |
RU2730864C1 (ru) | 2017-11-10 | 2020-08-26 | Редженесис Сайенс Ко., Лтд. | Способ производства культивируемых клеток и лекарственного препарата для лечения спинномозговых травм |
KR20190060716A (ko) * | 2017-11-24 | 2019-06-03 | 주식회사 차바이오랩 | 무혈청 배지 조성물 |
CN108774630A (zh) * | 2018-06-13 | 2018-11-09 | 中国科学院成都生物研究所 | 一种饰纹姬蛙骨骼肌细胞的原代培养方法 |
CN114127266A (zh) * | 2019-04-23 | 2022-03-01 | 雪拉托兹治疗株式会社 | 肌肉骨骼系统干细胞的选择性分化调节方法 |
WO2021158103A1 (en) * | 2020-02-03 | 2021-08-12 | Mosa Meat B.V. | Serum-free medium for culturing a bovine progenitor cell. |
CN115698264A (zh) * | 2020-04-01 | 2023-02-03 | 株式会社普里莫里斯 | 制备含有由脐带血干细胞分泌的高水平高效外来体的培养基的方法及其用途 |
CN111454898A (zh) * | 2020-04-23 | 2020-07-28 | 中科晟和干细胞技术有限公司 | 一种间充质干细胞培养基用于化妆品的制备方法 |
CN111808794B (zh) * | 2020-06-24 | 2022-04-22 | 江西博领生物技术有限公司 | 一种高效获取小鼠原代器官细胞的方法 |
CN116322718A (zh) * | 2020-10-07 | 2023-06-23 | 富士胶片株式会社 | 关节治疗用细胞制剂的制造方法、关节治疗用细胞制剂及间充质干细胞的培养方法 |
CN112391340A (zh) * | 2020-11-04 | 2021-02-23 | 深圳盛皓生物科技有限公司 | 一种间充质干细胞培养基 |
WO2023034384A1 (en) * | 2021-08-31 | 2023-03-09 | Steakholder Foods, LTD. | Methods and systems for adipocytes differentiation |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08308561A (ja) | 1995-05-16 | 1996-11-26 | Sumitomo Electric Ind Ltd | 動物細胞培養用無血清培地 |
JPH09191874A (ja) | 1996-01-22 | 1997-07-29 | Kurabo Ind Ltd | 正常ヒトメラニン細胞培養用無血清培地 |
JP2002529071A (ja) | 1998-11-09 | 2002-09-10 | コンソルツィオ・ペール・ラ・ジェスティオーネ・デル・チェントロ・ディ・ビオテクノロジー・アヴァンツァテ | 軟骨細胞様細胞のための無血清培地 |
JP2003516141A (ja) | 1999-12-07 | 2003-05-13 | モナシュ・ユニヴァーシティ | 長期細胞培養組成物とそれから誘導される遺伝的に修飾された動物 |
JP2005515777A (ja) | 2002-01-25 | 2005-06-02 | ジェンザイム・コーポレーション | 軟骨細胞のための無血清培地およびその使用法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO162160C (no) | 1987-01-09 | 1989-11-15 | Medi Cult As | Serumfritt vekstmedium, samt anvendelse derav. |
US5834418A (en) | 1996-03-20 | 1998-11-10 | Theratechnologies, Inc. | Process for the preparation of platelet growth factors extract |
US6328960B1 (en) | 1998-03-18 | 2001-12-11 | Osiris Therapeutics, Inc. | Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
JPWO2002022788A1 (ja) | 2000-09-12 | 2004-01-22 | 加藤 幸夫 | 間葉系幹細胞の培養方法 |
EP1511838A4 (en) | 2002-06-07 | 2007-01-10 | Es Cell Int Pte Ltd | METHOD FOR CONTROLLING DIFFERENTIATION IN STEM CELLS |
WO2004069172A2 (en) | 2003-01-30 | 2004-08-19 | The Government of the United States of America as represented by the Department of Veterans Affairs | Multilineage-inducible cells and uses thereof |
US20050032122A1 (en) * | 2003-08-06 | 2005-02-10 | Shiaw-Min Hwang | Optimizing culture medium for CD34<+> hematopoietic cell expansion |
US20060216821A1 (en) * | 2004-02-26 | 2006-09-28 | Reliance Life Sciences Pvt. Ltd. | Pluripotent embryonic-like stem cells derived from corneal limbus, methods of isolation and uses thereof |
JP2007536935A (ja) | 2004-05-14 | 2007-12-20 | ベクトン・ディキンソン・アンド・カンパニー | 間葉幹細胞の無血清増殖のための細胞培養環境 |
KR20050114107A (ko) * | 2004-05-31 | 2005-12-05 | 삼성전자주식회사 | 탈취필터가 구비된 세탁기 및 그 탈취방법 |
JP2007000077A (ja) | 2005-06-23 | 2007-01-11 | Hitachi Medical Corp | 付着性動物細胞の無血清培養方法及び付着性動物細胞の無血清培養用培地 |
JP2009519971A (ja) * | 2005-12-14 | 2009-05-21 | オルガノジェネシス インク. | スキンケア組成物及び治療法 |
KR101107835B1 (ko) | 2006-01-13 | 2012-02-09 | 가부시키가이샤 투셀 | 동물 세포의 무혈청 배양에 사용하기 위한 배양 배지 첨가물, 키트 및 이의 용도 |
WO2009114860A2 (en) | 2008-03-14 | 2009-09-17 | The Board Of Trustees Of The University Of Illinois | Activated mesenchymal stem cells for the prevention and repair of inflammatory states |
-
2007
- 2007-01-11 KR KR1020087019812A patent/KR101107835B1/ko active IP Right Grant
- 2007-01-11 WO PCT/JP2007/050232 patent/WO2007080919A1/ja active Application Filing
- 2007-01-11 US US12/160,481 patent/US9074176B2/en active Active
- 2007-01-11 AU AU2007205522A patent/AU2007205522B2/en active Active
- 2007-01-11 EP EP20070706579 patent/EP1988159B1/en active Active
- 2007-01-11 JP JP2007553929A patent/JP4385076B2/ja active Active
-
2015
- 2015-05-29 US US14/725,073 patent/US10184112B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08308561A (ja) | 1995-05-16 | 1996-11-26 | Sumitomo Electric Ind Ltd | 動物細胞培養用無血清培地 |
JPH09191874A (ja) | 1996-01-22 | 1997-07-29 | Kurabo Ind Ltd | 正常ヒトメラニン細胞培養用無血清培地 |
JP2002529071A (ja) | 1998-11-09 | 2002-09-10 | コンソルツィオ・ペール・ラ・ジェスティオーネ・デル・チェントロ・ディ・ビオテクノロジー・アヴァンツァテ | 軟骨細胞様細胞のための無血清培地 |
JP2003516141A (ja) | 1999-12-07 | 2003-05-13 | モナシュ・ユニヴァーシティ | 長期細胞培養組成物とそれから誘導される遺伝的に修飾された動物 |
JP2005515777A (ja) | 2002-01-25 | 2005-06-02 | ジェンザイム・コーポレーション | 軟骨細胞のための無血清培地およびその使用法 |
Non-Patent Citations (9)
Title |
---|
DOUCET C. ET AL.: "Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications", J. CELL PHYSIOL., vol. 205, no. 2, 2005, pages 228 - 236, XP002545728 * |
HORI C. AND OKA T.: "Induction by lithium ion of multiplication of mouse mammary epithelium in culture", PROC. NATL. ACAD. SCI. USA, vol. 76, no. 6, 1979, pages 2823 - 2827, XP003002660 * |
LABITZKE R. AND FRIEDL P.: "A serum-free medium formulation supporting growth of human umbilical cord vein endothelial cells in long-term cultivation", CYTOTECHNOLOGY, vol. 35, no. 2, 2001, pages 87 - 92, XP019236670 * |
SAITO Y. ET AL.: "Hissu Biryo Genso Selenium no Saibo Seizon Iji Sayo ni Kansuru Kenkyu", PROCEEDINGS OF THE JAPANESE CONFERENCE ON THE BIOCHEMISTRY OF LIPIDS, vol. 45, 2003, pages 262 - 265 * |
SAKAI K. ET AL.: "Use of nonionic surfactants for effective supply of phosphatidic acid in serum-free culture of Chinese hamster ovary cells", J. BIOSCI. BIOENG., vol. 92, no. 3, 2001, pages 256 - 261, XP002255475 * |
See also references of EP1988159A4 |
SHACTER E.: "Serum-free medium for growth factor-dependent and -independent plasmacytomas and hybridomas", J. IMMUNOL. METHODS, vol. 99, no. 2, 1987, pages 259 - 270, XP008039984 * |
WALTHALL B.J. AND HAM R.G.: "Multiplication of human diploid fibroblasts in a synthetic medium supplemented with EGF, insulin, and dexamethasone", EXP. CELL RES., vol. 134, no. 2, 1981, pages 303 - 311, XP003002908 * |
YAMAJI H. ET AL.: "Mukessei Baiyoka ni okeru CHO Saibo no Phospholipid ni yoru Zoshoku Sokushin Koka", THE SOCIETY OF CHEMICAL ENGINEERS MURORAN TAIKAI KENKYU HAPPYO KOEN YOSHISHU, 1998, pages 140 * |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9074176B2 (en) | 2006-01-13 | 2015-07-07 | Two Cells Co., Ltd. | Culture medium additive for use in serum-free culturing of animal cell, kit and use thereof |
US10184112B2 (en) | 2006-01-13 | 2019-01-22 | Two Cells Co., Ltd. | Culture medium additive for use in serum-free culturing of animal cell, kit and use thereof |
KR20100097649A (ko) | 2007-12-28 | 2010-09-03 | 후지레비오 가부시키가이샤 | 포유 동물 체세포용 배지 및 이를 위한 첨가제 |
WO2009084662A1 (ja) | 2007-12-28 | 2009-07-09 | Fujirebio Inc. | 哺乳動物体細胞用培地及びそのための添加剤 |
JP2016185962A (ja) * | 2008-10-21 | 2016-10-27 | ザ ジェネラル ホスピタル コーポレイション | 細胞移植 |
JP2014208654A (ja) * | 2008-10-21 | 2014-11-06 | ザ ジェネラル ホスピタル コーポレイション | 細胞移植 |
US9730963B2 (en) | 2008-10-21 | 2017-08-15 | The General Hospital Corporation | Cell transplantation |
JP2012506430A (ja) * | 2008-10-21 | 2012-03-15 | ザ ジェネラル ホスピタル コーポレイション | 細胞移植 |
US10131877B2 (en) | 2008-11-11 | 2018-11-20 | Two Cells Co., Ltd. | Differentiation-inducing culture medium additive and use thereof |
US20110212523A1 (en) * | 2008-11-11 | 2011-09-01 | Yukio Kato | Differentiation-inducing culture medium additive and use thereof |
KR20110084281A (ko) | 2008-11-11 | 2011-07-21 | 고쿠리츠다이가쿠호진 히로시마다이가쿠 | 분화 유도 배지용 첨가제 및 그의 용도 |
WO2010055616A1 (ja) | 2008-11-11 | 2010-05-20 | 独立行政法人科学技術振興機構 | 分化誘導培地用添加剤およびその利用 |
JP5660572B2 (ja) * | 2008-11-11 | 2015-01-28 | 国立大学法人広島大学 | 分化誘導培地用添加剤およびその利用 |
US20160032247A1 (en) * | 2008-11-11 | 2016-02-04 | Hiroshima University | Differentiation-inducing culture medium additive and use thereof |
AU2009315204B2 (en) * | 2008-11-11 | 2015-03-26 | Two Cells Co., Ltd. | Additive for differentiation induction culture medium, and use thereof |
JP2010193723A (ja) * | 2009-02-23 | 2010-09-09 | Fujirebio Inc | 骨細胞への分化誘導培地及び方法 |
WO2010095685A1 (ja) * | 2009-02-23 | 2010-08-26 | 富士レビオ株式会社 | 骨細胞への分化誘導培地及び方法 |
CN102791276A (zh) * | 2010-03-10 | 2012-11-21 | 智再如股份有限公司 | 含有间充质干细胞的细胞制品及其制造方法 |
US9394521B2 (en) | 2010-03-10 | 2016-07-19 | Two Cells Co., Ltd. | Cell preparation containing mesenchymal stem cells, and method for producing same |
JP5804385B2 (ja) * | 2010-03-10 | 2015-11-04 | 株式会社ツーセル | 間葉系幹細胞を含む細胞製剤及びその製造方法 |
WO2011111787A1 (ja) | 2010-03-10 | 2011-09-15 | 株式会社ツーセル | 間葉系幹細胞を含む細胞製剤及びその製造方法 |
JP2012524551A (ja) * | 2010-04-30 | 2012-10-18 | 中国科学院広州生物醫薬與健康研究院 | 培養培地添加物及びその応用 |
JP2012029684A (ja) * | 2010-06-30 | 2012-02-16 | Cell Aid Kenkyusho:Kk | 細胞の製造方法 |
US10184110B2 (en) | 2010-08-06 | 2019-01-22 | The General Hospital Corporation | System and apparatus for cell treatment |
JP2014533113A (ja) * | 2011-11-11 | 2014-12-11 | エッセンシャル ファーマシューティカル エルエルシー | 血清代替物および不安定因子を備えるキット |
WO2015016357A1 (ja) * | 2013-08-01 | 2015-02-05 | 株式会社ツーセル | 軟骨損傷治療剤及びその製造方法 |
US10507266B2 (en) | 2013-08-01 | 2019-12-17 | Two Cells Co., Ltd. | Cartilage-damage treatment agent and method for producing same |
JPWO2015016357A1 (ja) * | 2013-08-01 | 2017-03-02 | 株式会社ツーセル | 軟骨損傷治療剤及びその製造方法 |
JP2017506511A (ja) * | 2014-02-14 | 2017-03-09 | ナショナル ユニバーシティー オブ アイルランド, ゴールウェイ | 無血清培地 |
JPWO2016136986A1 (ja) * | 2015-02-27 | 2017-12-07 | ロート製薬株式会社 | 間葉系幹細胞培養用培地、間葉系幹細胞の培養方法及び間葉系幹細胞 |
WO2016136986A1 (ja) * | 2015-02-27 | 2016-09-01 | ロート製薬株式会社 | 間葉系幹細胞培養用培地、間葉系幹細胞の培養方法及び間葉系幹細胞 |
JP2018506986A (ja) * | 2015-03-04 | 2018-03-15 | メゾブラスト・インターナショナル・エスアーエールエル | 間葉系幹細胞の細胞培養法 |
JP2021090463A (ja) * | 2015-03-04 | 2021-06-17 | メゾブラスト・インターナショナル・エスアーエールエル | 間葉系幹細胞の細胞培養法 |
JP7410899B2 (ja) | 2015-03-04 | 2024-01-10 | メゾブラスト・インターナショナル・エスアーエールエル | 間葉系幹細胞の細胞培養法 |
JP7113430B2 (ja) | 2016-12-28 | 2022-08-05 | 株式会社ツーセル | 生体組織損傷の修復剤および当該修復剤の製造方法 |
KR20190102015A (ko) | 2016-12-28 | 2019-09-02 | 가부시키가이샤 투셀 | 생체 조직 손상의 수복제 및 그 수복제의 제조 방법 |
JPWO2018123968A1 (ja) * | 2016-12-28 | 2019-10-31 | 株式会社ツーセル | 生体組織損傷の修復剤および当該修復剤の製造方法 |
WO2018123968A1 (ja) | 2016-12-28 | 2018-07-05 | 株式会社ツーセル | 生体組織損傷の修復剤および当該修復剤の製造方法 |
JP2020162536A (ja) * | 2019-03-29 | 2020-10-08 | 興人ライフサイエンス株式会社 | 組み換えタンパク質産生増加のための培地用組成物 |
WO2021060460A1 (ja) | 2019-09-26 | 2021-04-01 | 株式会社ツーセル | 生体組織損傷の修復剤の製造方法および生体組織損傷の修復剤 |
KR20220066959A (ko) | 2019-09-26 | 2022-05-24 | 가부시키가이샤 투셀 | 생체 조직 손상 수복제의 제조 방법 및 생체 조직 손상 수복제 |
CN112852719A (zh) * | 2019-11-12 | 2021-05-28 | 武汉济源高科技有限公司 | 一种临床级干细胞无血清培养基 |
CN112852719B (zh) * | 2019-11-12 | 2022-07-15 | 武汉济源高科技有限公司 | 一种临床级干细胞无血清培养基 |
KR20230054445A (ko) | 2020-09-03 | 2023-04-24 | 가부시키가이샤 투셀 | 중추신경 질환의 치료용 조성물, 중추신경 질환의 치료용 조성물의 제조 방법 및 중추신경 질환의 치료용 제재의 제조 방법 |
WO2022049977A1 (ja) | 2020-09-03 | 2022-03-10 | 株式会社ツーセル | 中枢神経疾患の治療用組成物、中枢神経疾患の治療用組成物の製造方法および中枢神経疾患の治療用製剤の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
US10184112B2 (en) | 2019-01-22 |
EP1988159A1 (en) | 2008-11-05 |
US20100279412A1 (en) | 2010-11-04 |
EP1988159B1 (en) | 2014-03-05 |
JPWO2007080919A1 (ja) | 2009-06-11 |
AU2007205522A1 (en) | 2007-07-19 |
EP1988159A4 (en) | 2009-05-06 |
KR101107835B1 (ko) | 2012-02-09 |
US20150267172A1 (en) | 2015-09-24 |
JP4385076B2 (ja) | 2009-12-16 |
US9074176B2 (en) | 2015-07-07 |
AU2007205522B2 (en) | 2011-08-11 |
KR20080091809A (ko) | 2008-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007080919A1 (ja) | 動物細胞を無血清培養するための培地用添加剤、キット及びこれらの利用 | |
JP5872046B2 (ja) | 間葉系幹細胞の基本培養培地の調製方法 | |
CN106906182B (zh) | 一种间充质干细胞无血清培养基 | |
US7169610B2 (en) | Serum-free media for chondrocytes and methods of use thereof | |
US11634690B2 (en) | Agent for accelerating growth of pluripotent stem cells | |
US9394521B2 (en) | Cell preparation containing mesenchymal stem cells, and method for producing same | |
EP3074505B1 (en) | Serum-free medium | |
Tang et al. | Evolving concepts of chondrogenic differentiation: history, state-of-the-art and future perspectives | |
KR20090076989A (ko) | 태반 줄기세포군으로 뼈의 결함을 치료하기 위한 방법과 조성물 | |
US20230117670A1 (en) | Bioactive substance composition, serum-free medium comprising the composition, and uses thereof | |
KR20110084281A (ko) | 분화 유도 배지용 첨가제 및 그의 용도 | |
WO2021254296A1 (zh) | 一种生物活性物质组合物、包含所述组合物的无血清培养基及其用途 | |
TW200927927A (en) | Stem cell medium | |
Adolphe et al. | Different Types of Cultured Chondrocytes—the In Vitro Approach to the Study Ofbiological Regulation | |
Schecroun et al. | In vitro growth and osteoblastic differentiation of human bone marrow stromal cells supported by autologous plasma | |
AU2013202314B2 (en) | Culture medium for human mesenchymal stem cells | |
Chen et al. | Stemness distinctions between the ectomesenchymal stem cells from neonatal and adult mice | |
NZ616977B (en) | Culture medium for human mesenchymal stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007553929 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12160481 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007205522 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007706579 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007205522 Country of ref document: AU Date of ref document: 20070111 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087019812 Country of ref document: KR |